Background: Glioblastoma (GBM IDH-wildtype WHO 2021) is an aggressive central nervous system malignancy with a poor prognosis despite standard therapy. Integrative oncology approaches involving natural compounds have shown potential in preclinical studies to enhance the efficacy of chemoradiotherapy.Methods: This prospective, longitudinal observational pilot study, lacking a randomized control group, followed 72 newly diagnosed glioblastoma patients (diagnosed by histological examination and MGMT promoter molecular study alone, grade 4 glioma patients) treated with the STUPP protocol. This group could voluntarily opt to receive integrative therapy (IT), which included polydatin, curcumin, andBoswellia serrata, in addition to standard care. Survival outcomes were compared between IT-adherent and non-adherent patients. Multivariate Cox regression was employed to adjust for potential confounders, including age, extent of surgical resection, and corticosteroid use.Results: The median overall survival (OS) for the entire cohort was 13.3 months. Patients who adhered to IT (n = 60) had a median OS of 25.4 months, which increased to 34.4 months for those who underwent gross total resection. The non-IT group (n = 12) exhibited a median OS of 10.6 months. Multivariate analysis confirmed that IT adherence and the extent of resection were independent predictors of prolonged survival (p< 0.05). No severe adverse events were reported with IT.Conclusions: Integrative therapy combining polydatin, curcumin, andBoswellia serratawith standard treatment would appear to be associated with prolonged survival in glioblastoma patients, particularly among those who underwent gross total resection. However, the small size of the control group, the absence of randomization, and the inclusion solely of primary glioblastoma limit the generalizability of these findings. These results underscore the need for further investigation through randomized controlled trials.
背景：胶质母细胞瘤（GBM IDH野生型，WHO 2021分类）是一种侵袭性中枢神经系统恶性肿瘤，即使接受标准治疗，其预后仍然较差。临床前研究表明，包含天然化合物的整合肿瘤学方法可能增强放化疗的疗效。 方法：这项前瞻性、纵向观察性初步研究，未设置随机对照组，共纳入72例新诊断的胶质母细胞瘤患者（仅通过组织学检查和MGMT启动子分子研究确诊的4级胶质瘤患者），所有患者均接受STUPP方案治疗。该组患者可自愿选择在标准治疗基础上接受整合治疗，包括白藜芦醇苷、姜黄素和乳香提取物。研究比较了坚持整合治疗与未坚持治疗患者的生存结局，并采用多变量Cox回归模型调整年龄、手术切除范围和皮质类固醇使用等潜在混杂因素。 结果：整个队列的中位总生存期为13.3个月。坚持整合治疗的患者（n=60）中位总生存期为25.4个月，其中接受肿瘤全切除的患者中位总生存期延长至34.4个月。未接受整合治疗的对照组（n=12）中位总生存期为10.6个月。多变量分析证实，坚持整合治疗和手术切除范围是延长生存期的独立预测因素（p<0.05）。整合治疗未报告严重不良事件。 结论：将白藜芦醇苷、姜黄素和乳香提取物与标准治疗相结合的整合疗法，似乎与胶质母细胞瘤患者生存期的延长相关，特别是在接受肿瘤全切除的患者中。然而，对照组样本量较小、缺乏随机化设计以及仅纳入原发性胶质母细胞瘤患者，限制了这些研究结果的普适性。这些发现强调了通过随机对照试验进一步研究的必要性。
肿瘤(癌症)患者之家